Belviq® Lawsuit Attorneys
Belviq® and Belviq XR® Weight-Loss Drug Recalled
Did you or a loved one take Belviq or Belviq XR for weight-loss? You may be at risk for cancer, including pancreatic, colorectal and lung cancer.
The U.S. Food and Drug Administration (FDA) announced that Japanese drug maker, Eisai Inc., has agreed to voluntarily withdraw its weight-loss drugs, Belviq (lorcaserin) and long-acting form, Belviq XR, after studies showed an increased risk of cancer in patients.
The FDA requested the withdrawal based on a five (5) year study involving 12,000 patients. The study showed that patients taking Belviq® were diagnosed with cancer at a higher rate than patients taking a placebo.
The FDA has recommended that patients should stop taking Belviq and should talk to their doctor about options for alternative weight-loss medications.
Belviq® Cancer Study
On February 13, 2020, the FDA declared that the drug maker has arranged to withdraw Belviq from the U.S. market.
In 2012, Belviq (lorcaserin) was approved for weight-loss. The manufacturer, Japanese drug company Eisai, Inc., was required to conduct long-term safety studies into cardiac safety. The FDA’s review of the study in January of 2020 showed no heart risk, but revealed the increased risk of cancer.
The results of the five-year study showed an increase in the overall cancer rate for the Belviq group compared to the placebo group with comprehensive use. Pancreatic cancer, colorectal cancer, and lung cancer were particularly present in Belviq users.
If you or a loved one took Belviq or Belviq XR and were diagnosed with cancer, fill out the form on this page or call right now for a free consultation. You may be eligible for compensation for the harm caused and should seek legal advice.
Get Your Free Case Evaluation!